Nama's AI scorecard currently rates ADMA Biologics Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ADMA's P/E ratio?

ADMA Biologics trades at a trailing price-to-earnings ratio of 16.1.

When does ADMA report earnings?

ADMA Biologics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.24.

What is the ADMA price target?

The median analyst price target from 4 analysts is $17.50, with a range of $12.00 – $21.00.

Is ADMA Shariah compliant?

Nama's AAOIFI-style screen reads ADMA Biologics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

ADMA Biologics (ADMA)

Healthcare · Biotechnology · NASDAQ

ADMA Biologics (ADMA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.82B, a trailing price-to-earnings ratio of 16.1 and a free-cash-flow yield of 0.9%. Over the most recent reported fiscal year, revenue grew 19.6% and free cash flow per share fell 75.2%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 8.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Lagging · -27.7% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-50.4%

How far the last close sits under the highest price of the past five years.

Market cap	$2.82B
Trailing P/E	16.1
Price / book	7.0
Price / sales	5.6
FCF yield	0.9%
Dividend yield	—
Gross margin	64.7%
Operating margin	42.3%
Net margin	33.0%
Revenue growth (YoY)	+19.6%
Revenue growth (3-yr annual)	+49.0%
EPS growth (YoY)	+26.0%
FCF/share growth (YoY)	-75.2%
Beta	0.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ADMA earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.24). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.23	$0.20	+15.0%	$141.10M
Q2 2026	Aug 5, 2026	$0.17	$0.16	+6.2%	$124.39M
Q1 2026	May 6, 2026	$0.17	$0.20	-15.0%	$114.49M
Q4 2025	Feb 25, 2026	$0.22	$0.20	+10.0%	$139.16M

ADMA analyst price target

Median target $17.50 from 4 analysts, ranging $12.00 – $21.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ADMA data on Nama Insights →

ADMA FAQ

Is ADMA a buy?: Nama's AI scorecard currently rates ADMA Biologics Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ADMA's P/E ratio?: ADMA Biologics trades at a trailing price-to-earnings ratio of 16.1.
When does ADMA report earnings?: ADMA Biologics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.24.
What is the ADMA price target?: The median analyst price target from 4 analysts is $17.50, with a range of $12.00 – $21.00.
Is ADMA Shariah compliant?: Nama's AAOIFI-style screen reads ADMA Biologics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.